Amgen Inc.

Amgen Fremont Inc.

Amgen Canada Inc.

Giorgio Senaldi

Orit Foord

Scott L Klakamp

Raffaella Faggioni

Larry L Green

Jaspal Singh Kang

Palaniswami Rathanaswami

Kathy Manchulenko

Ian Nevin Foltz

Mary Haak-Frendscho

Tak Wah Mak

Meina Liang

John Stephen Babcook

Xiao Feng

Qiaojuan Jane Su

Steven Kiyoshi Yoshinaga

Scott Michael Silbiger

Lars Eyde Theill

Yen-Wah Lee

Kiran Ahluwalia

Richard Yeh

Gang Yu

Anna Tafuri Bladt

Amy K Schneider

Arda Shahinian

Craig Pigott

Bruce Alan Keyt

Xiao-Dong Yang

Gadi Gazit-Bornstein

Gerardo Zapata

Rozanne Lee

Scott Klakamp

Meina L Liang

Kathy Manchulencho

Quiaojuan Jane Su

Polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding the polypeptides, and vectors and host cells for expressing the polypeptides are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.

Polypeptides involved in immune response

Antibodies directed to the antigen TNF&#x3b1; and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNF&#x3b1;. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Antibodies directed to tumor necrosis factor and uses thereof

The present invention is related to antibodies directed to IL-13 and uses of such antibodies. For example, in accordance with the present invention, there are provided human monoclonal antibodies directed to IL-13. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), are provided. Additionally, methods of using these antibodies to treat patients are also provided. Additionally, IL-13 dependent biomarkers and methods of their identification and use are also provided.

Fully human monoclonal antibodies to IL-13

Antibodies directed to the antigen IL-1&#x3b2; and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen IL-1&#x3b2;. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Antibodies against interleukin-1 &#x3b2;

Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.

Antibody to TNF receptor-like molecules

Antibodies against interleukin-1&#x3b2;

The present invention is related to antibodies directed to the antigen properdin and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen properdin. Nucleotide sequences encoding, and polypeptides comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Anti-properdin antibodies, and methods for making and using same

Antibodies directed to tumor necrosis factor

Nucleic acids encoding MK61 receptors

Disclosed are novel methods and compositions for treating IgE-related diseases using NNT-1 inhibitors. In one embodiment, the present invention relates to a method of treating IgE-related diseases using a selective binding agent to NNT-1. In another embodiment, the present invention relates to a method of treating IgE-related diseases using an NNT-1 expression modulator. Methods of modulating IgE levels, and of diagnosing, preventing and/or treating certain types of allergic diseases using NNT-1 inhibitors are also disclosed.

Methods and compositions for treating IgE-related disease using NNT-1 inhibitors

Growing community of inventors

Dublin, CA, United States of America

Giorgio Senaldi